← Stock Trading Canary · All insider profiles
INSIDER PROFILE · UK
Graeme Proudfoot
Director of BioPharma Credit PLC | Director of The Schiehallion Fund Limited
Profile key: uk|graeme proudfoot
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 2
- Purchases · 24M
- 2
- Average purchase
- USD 67,018
- Gross purchase value
- USD 134,035
- Last purchase
- 2026-09-30
- Completed 20D events
- 0.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: BioPharma Credit PLC
Companies: BioPharma Credit PLC | The Schiehallion Fund Limited
Post-purchase outcomes
Benchmark-relative outcomes are available against FTSE 100.
- Excess return = stock return − FTSE 100 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +1.6% | +1.6% | +1.4% |
| 20D | 0No data | Awaiting maturity | — | — | — | — |
| 60D | 0No data | Awaiting maturity | — | — | — | — |
| 120D | 0No data | Awaiting maturity | — | — | — | — |
Research patterns
- First purchase in 12M
- 2/2
- Large purchase ≥ €100k
- 0/2
- Cluster buying · 15D
- 0/2
- Buying the dip · ≥20% below prior 52W high
- 0/2
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.